` 4506 (Sumitomo Pharma Co Ltd) vs Nikkei 225 Comparison - Alpha Spread

4506
vs
N
Nikkei 225

Over the past 12 months, Sumitomo Pharma Co Ltd has significantly outperformed Nikkei 225, delivering a return of +231% compared to the Nikkei 225's +72% growth.

Stocks Performance
4506 vs Nikkei 225

Loading
4506
Nikkei 225
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
4506 vs Nikkei 225

Loading
4506
Nikkei 225
Difference
www.alphaspread.com

Performance By Year
4506 vs Nikkei 225

Loading
4506
Nikkei 225
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Sumitomo Pharma Co Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Sumitomo Pharma Co Ltd
Glance View

Market Cap
824.8B JPY
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Sumitomo Pharma Co. Ltd. stands as a testament to innovation and resilience. Emerging from its roots in Sumitomo Dainippon Pharma, this Japanese giant has been weaving a complex tapestry of cutting-edge medical advancements and strategic mergers for decades. At its core, Sumitomo Pharma is fueled by an unwavering commitment to research and development, driving its efforts in therapeutic areas such as psychiatry, neurology, and oncology. These focal points aren't mere business segments but vital lifelines that the company seeks to improve with its products. Their success heavily relies on their ability to translate research into actionable, marketable treatments; it's a dance between science and commerce, with the rhythm dictated by patient needs and market demands. Sumitomo Pharma's financial engine is powered not just by their innovative drug pipeline but also through savvy global partnerships and strategic acquisitions. By expanding its footprint across North America, Europe, and Asia, the company meticulously builds a global distribution network that ensures its products reach the hands of physicians and patients worldwide. This extensive reach allows Sumitomo Pharma to tap into diverse markets, fueling both sales and brand recognition. Moreover, through its alliances with biotech firms and academic institutions, the company enhances its research capabilities, fostering a cycle of innovation that feeds back into its financial growth. In essence, Sumitomo Pharma doesn't just participate in the pharmaceutical industry; it actively shapes it, both through its dedication to breakthrough therapies and its strategic navigation of complex global markets.

Intrinsic Value
1 242.71 JPY
Overvaluation 40%
Intrinsic Value
Price ¥2 073
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett